(MENAFN- GlobeNewsWire - Nasdaq) The key market opportunities in the pneumococcal vaccine sector are driven by expanding PCVs, scaling intramuscular delivery, and enhancing adult immunization. Growth prospects lie in public health agency distribution, emerging markets, and strategic collaborations, with a focus on innovation and targeted R&D.Dublin, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The "Pneumococcal Vaccine Market Opportunities and Strategies to 2034" has been added to ResearchAndMarkets's offering.
The comprehensive report on the global pneumococcal vaccine market provides insights into historical and forecast periods spanning 2019-2024 and beyond to 2034. It meticulously examines regional trends and key economies, projecting a notable growth trajectory.
As of 2024, the global market for pneumococcal vaccines was valued at $7.92 billion, progressing with a CAGR of 4.17% since 2019. Projections indicate a rise to $10.04 billion by 2029, with a further increase to $12.41 billion by 2034, driven by a CAGR of 4.33%. This growth is attributed to increased pneumococcal incidences, heightened healthcare investments, and proactive immunization campaigns, despite challenges like stringent regulations and misinformation.
![]()
Future growth is expected, propelled by an aging demographic, a rise in chronic respiratory ailments, and the intensifying demand for pediatric vaccination. However, hurdles such as vaccine costs, cold chain challenges, and geopolitical tensions may impede progress.
Regionally, North America dominated the market in 2024, capturing 52.01% or $4.12 billion. Asia-Pacific and South America are anticipated to emerge as the fastest-growing regions, with CAGRs of 6.31% and 5.71%, respectively. Eastern Europe and the Middle East are also poised for growth.
The market remains highly concentrated, with major players like Pfizer Inc. leading with an 82.01% market share, followed by Merck & Co. Inc., GlaxoSmithKline plc, and the Serum Institute of India Pvt. Ltd.
Product segmentation reveals that pneumococcal conjugate vaccines (PCVs) dominated the market in 2024, comprising 96.68% or $7.66 billion. The PCVs segment is forecasted to expand substantially at a CAGR of 5.15% from 2024 to 2029.
By administration route, intramuscular vaccines led with 99.17% of the market share in 2024. This segment is anticipated to maintain its growth trajectory with a 4.92% CAGR until 2029.
Distribution channel analysis identifies public health agencies as the largest segment, holding a 47.33% share in 2024. Their influence is expected to grow, driven by a CAGR of 6.68% between 2024 and 2029. The pediatrics segment, commanding 77.70% of the end-user market share, is projected to continue its dominance. Nevertheless, the adult segment is expected to see the fastest growth at a CAGR of 6.74%.
Opportunities abound, particularly in the pneumococcal conjugate vaccines and intramuscular segment, predicting significant increases in global sales by 2029. The U.S. market is set to gain $983.14 million alone.
Several market trends are noteworthy: innovation in vaccines, strategic collaborations, advancements in conjugate vaccine science, and the pursuit of broader serotype coverage. Companies are encouraged to capitalize on these opportunities through region-specific innovations, adult-focused developments, strategic partnerships, and competitive pricing strategies.
Success in the pneumococcal vaccine market will demand targeted digital and traditional marketing, healthcare provider partnerships, and expansion in emerging markets. Emphasis on adult vaccine uptake and strengthening alliances with public health agencies remain critical.
Why You Should Purchase This Report:
Gain global insights from the most extensive report on the pneumococcal vaccine market. Examine the influence of the coronavirus and project the market's recovery and expansion as its impact diminishes. Formulate regional and national strategies using detailed local data and analyses. Identify promising growth segments for targeted investments. Leverage predictive data for outperforming competitors by understanding market drivers and trends. Access fresh market research to better understand customer needs. Benchmark organizational performance against key competitors. Utilize interconnected data sets for strategic planning. Support presentations with robust, high-quality data and analyses.
Markets Covered:
1) Product Types: Pneumococcal Conjugate Vaccine (PCVs), Pneumococcal Polysaccharide Vaccine (PPV)
2) Administration Routes: Intramuscular, Subcutaneous
3) Distribution Channels: Pharmacies, Community Clinics, Public Health Agencies, Others
4) End Users: Pediatrics, Adults
Companies Profiled: Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd.
Countries: Australia, China, India, Indonesia, Japan, South Korea, USA, Canada, Brazil, France, Germany, UK, Italy, Spain, Russia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Data Specifics:
Five-year historic data and ten-year forecast period Market size and growth ratios in relation to related markets GDP proportions, per capita expenditure, and vaccine market indicators Comprehensive national and regional data with historical and forecast analysis
Key Attributes
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment